In this video, Dharam Kaushik, MD, discusses the favorable outcomes of perioperative yoga in patients with prostate cancer. This study was presented recently at the 2021 American Urological Association Annual Meeting. Kaushik is an associate professor and chair of urologic research in the department of urology and the program director of Urologic Oncology Fellowship at the University of Texas Health, San Antonio
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.
2-year data show continued enfortumab vedotin efficacy in cisplatin-ineligible MIBC
June 3rd 2024Updated findings from cohort H of the EV-103 study showed promising 2-year event-free survival outcomes and favorable antitumor activity with enfortumab vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer.
TKIs show modest activity in lenvatinib-exposed patients with advanced renal cell carcinoma
June 2nd 2024Patients with advanced renal cell carcinoma treated with TKIs in the second or third line following lenvatinib treatment showed modest activity, highlighting the need for improved treatment options.
Sacituzumab Govitecan yields ‘limited efficacy’ post-EV in real-world mUC study
June 2nd 2024A retrospective cohort of patients with metastatic urothelial cancer who received prior enfortumab vedotin had low efficacy when treated with sacituzumab govitecan, with the best outcomes coming from directly sequencing the 2 agents.